Not recruiting
COVID-19
Not recruitingRegistered drug
Study on Abatacept for Improving Recovery in Hospitalized COVID-19 Patients
Registered drug
Countries:
Poland
Poland- Participants:18–64 years · 65+ years
- Substances:Abatacept
Find therapies in clinical trials near you – page 135
- recruiting
- 3 968
- countries
- 28
- conditions
- 2 103
3 968 trials recruiting28 European countries2 103 conditions coveredUpdated today
1 804 trials match your criteria
Not recruiting
Asthma
Not recruitingRegistered drug
Study on RPT193 for Adults with Moderate-to-Severe Asthma Partially Controlled by Inhaled Corticosteroids and Long-Acting Beta 2 Agonists
Registered drug
- Disease:Asthma
- Substances:Salbutamol SulfateSalmeterol+2
Countries:Poland
Poland- Participants:18–64 years · 65+ years
- Substances:Salbutamol Sulfate
Not recruiting
Endometrial cancer
Not recruitingRegistered drugNo placebo
Study of Pembrolizumab and Lenvatinib for Patients with Advanced or Recurrent Endometrial Cancer
Registered drugNo placebo
- Disease:Endometrial cancer
- Substances:CarboplatinLenvatinib+2
Countries:Poland
Poland- Participants:18–64 years · 65+ years
- Substances:Carboplatin
Not recruiting
Dry eye+1
Not recruitingRegistered drug
Study on Long-Term Safety and Efficacy of Ianalumab for Patients with Sjögren’s Syndrome
Registered drug
- Disease:Dry eyeSjogren's syndrome
- Substances:EmtricitabineEntecavir+4
Countries:Poland
Poland- Participants:18–64 years · 65+ years
- Substances:Emtricitabine
Not recruiting
Diffuse large B-cell lymphoma refractory
Not recruitingRegistered drug
Study on Brentuximab Vedotin, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Registered drug
- Disease:Diffuse large B-cell lymphoma refractory
- Substances:Brentuximab VedotinLenalidomide+1
Countries:Poland
Poland- Participants:18–64 years · 65+ years
- Substances:Brentuximab Vedotin
Not recruiting
Axial spondyloarthritis
Not recruitingRegistered drug
Study on Tofacitinib for Patients with Early Active Axial Spondyloarthritis Who Did Not Respond to NSAIDs
Registered drug
- Disease:Axial spondyloarthritis
- Substances:NaproxenTofacitinib
Countries:Poland
Poland- Participants:18–64 years
- Substances:Naproxen
Not recruiting
IgA nephropathy
Not recruitingRegistered drug
Study on the Effectiveness and Safety of RO7434656 for Patients with Primary IgA Nephropathy at High Risk of Progression
Registered drug
- Disease:IgA nephropathy
- Substances:Isis 696844
Countries:Poland
Poland- Participants:18–64 years · 65+ years
- Substances:Isis 696844
Not recruiting
Cholangiocarcinoma
Not recruitingInvestigationalNo placebo
Study of Futibatinib for Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements
InvestigationalNo placebo
- Disease:Cholangiocarcinoma
- Substances:Futibatinib
Countries:Poland
Poland- Participants:18–64 years · 65+ years
- Substances:Futibatinib
Not recruiting
Chronic lymphocytic leukaemia+1
Not recruitingInvestigationalNo placebo
Study Comparing Ibrutinib and Venetoclax with Chlorambucil and Obinutuzumab for First-line Treatment in Patients with Chronic Lymphocytic Leukemia
InvestigationalNo placebo
- Disease:Chronic lymphocytic leukaemiaB-cell small lymphocytic lymphoma
- Substances:Ibrutinib
Countries:Poland
Poland- Participants:18–64 years · 65+ years
- Substances:Ibrutinib
Not recruiting
Non-small cell lung cancer metastatic
Not recruitingRegistered drugNo placebo
Study Comparing Pembrolizumab Alone and with Sacituzumab Govitecan for Patients with Metastatic Non-Small Cell Lung Cancer with High PD-L1 Levels
Registered drugNo placebo
- Disease:Non-small cell lung cancer metastatic
- Substances:Pembrolizumab
Countries:Poland
Poland- Participants:18–64 years · 65+ years
- Substances:Pembrolizumab
Not recruiting
Leiomyosarcoma metastatic
Not recruitingRegistered drugNo placebo
Study of Lurbinectedin and Doxorubicin for First-line Treatment in Patients with Metastatic Leiomyosarcoma
Registered drugNo placebo
- Disease:Leiomyosarcoma metastatic
- Substances:FilgrastimLurbinectedin+3
Countries:Poland
Poland- Participants:18–64 years · 65+ years
- Substances:Filgrastim
Not recruiting
Colitis ulcerative
Not recruitingInvestigationalNo placebo
Study on Upadacitinib for Children with Moderate to Severe Ulcerative Colitis
InvestigationalNo placebo
- Disease:Colitis ulcerative
- Substances:Upadacitinib
Countries:Poland
Poland- Participants:0–17 years
- Substances:Upadacitinib